Transcriptome analysis of circulating tumor cells from patients before and after treatment with acalabrutinib. (A) Principal component analysis of samples collected at baseline (●), after 1 cycle (♦), and after 6 cycles (▪). (B) Heatmap of DE genes (fold-change ≥2, FDR < 0.1) (C) Average ± SEM log₂ fold-change in expression of leading-edge genes of the indicated gene signatures after 1 cycle and after 6 cycles compared with baseline. (D) Average ± SEM log₂ fold-change in leading edge genes from BCR and nuclear factor-κB signatures in the BID group compared with the QD group. *P < .05, **P < .01, ***P < .001.